John Ausiello, MD
Basic profileJohn Ausiello is an Endocrinology/Metabolic physician affiliated with NewYork–Presbyterian Hospital. OpenAlex indexes 16 publications with 8,683 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Adult Growth Hormone Deficiency and Cardiovascular Risk
Sponsor: Columbia University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20257 payments$163
- Ascendis Pharma Endocrinology IncProgram year20254 payments$112
- Amgen Inc.Program year20254 payments$89
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
64.4%l-Thyroxine56%Levothyroxine Sodium80%Synthroid20%Part D≥157 patientsThyroid Hormone Synthesis Inhibitor4.2%Methimazole100%Part D≥16 patients+ 2 more classes in this area
Metabolism & gastrointestinal
11.2%Corticosteroid7.7%Prednisone100%Part D≥28 patientsBiguanide (metformin)2.1%Metformin Hcl Er100%Part D<11 patients+ 1 more class in this area
Sensory organs
10.8%Corticosteroid10.8%Hydrocortisone80%Dexamethasone20%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Heart rate variability and adrenal size provide clues to sudden cardiac death in hospitalized COVID-19 patients
Journal of Critical Care
2022 - Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19
Reviews in Endocrine and Metabolic Disorders
2021 - Ectopic ACTH Syndrome Emerging 5 Years after the Diagnosis of Neuroendocrine Tumor
Case Reports in Endocrinology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Melana Yuzefpolskaya, MD
NewYork–Presbyterian Hospital
Kevin Clerkin, MD
NewYork–Presbyterian Hospital
Brandon Swed, MD
NewYork–Presbyterian Hospital
Lawrence Lenke, MD
NewYork–Presbyterian Hospital
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”